Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 11:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 997 matching trials from the live ClinicalTrials.gov search.
Conditions
Kidney Transplant
Interventions
Infliximab, Methylprednisolone, Mycophenolate Mofetil, Tacrolimus, Thymoglobulin®, Acetaminophen, Loratadine, Placebo for Infliximab, Prednisone, Diphenhydramine
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
13
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 8 more
Conditions
Relapsed Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
Interventions
Nivolumab, Pembrolizumab
Biological
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2037
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Lymphoma, Large-Cell, Ki-1, Lymphoma, T-Cell
Interventions
UCN-01 (7-hydroxystaurosporine)
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Cataract
Interventions
Acular, Xibrom
Drug
Lead sponsor
Innovative Medical
Industry
Eligibility
21 Years and older
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Wilkes-Barre, Pennsylvania
Conditions
Rosacea, Erythematotelangiectatic
Interventions
Trametinib
Drug
Lead sponsor
Albany Research Institute, Inc.
Other
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Albany, New York
Completed No phase listed Observational Accepts healthy volunteers

Prepulse Inhibition in Youth Contact Sports Players

NCT04058184
Conditions
Reflex, Abnormal
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
13 Years to 19 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Active, not recruiting Phase 3 Interventional Results available

A Study of Guselkumab in Participants With Active Psoriatic Arthritis

NCT04882098
Conditions
Arthritis, Psoriatic
Interventions
Guselkumab, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
1,054 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
23
States / cities
Birmingham, Alabama • Flagstaff, Arizona • Glendale, Arizona + 20 more
Conditions
Contraception
Interventions
Miglustat (Zavesca)
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Solid Tumor, Solid Carcinoma, Solid Tumor, Adult, Hematologic Malignancy
Interventions
Benralizumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 85 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 2 more
Conditions
Cardiac Surgery Subjects, Subjects Undergoing CABG and/or Cardiac Valve Replacement
Interventions
sitaxsentan (Thelin), Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
48 Years to 82 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
3
States / cities
Philadelphia, Pennsylvania • Charleston, South Carolina • Chattanooga, Tennessee
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Acalabrutinib (Arm A), Acalabrutinib (Arm B)
Drug
Lead sponsor
Acerta Pharma BV
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Alcohol Use Disorder (AUD), PTSD
Interventions
CBT + expressive writing, Wait-List Control
Behavioral
Lead sponsor
University of Rhode Island
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Providence, Rhode Island
Conditions
Reperfusion Injury, Post Cardiac Arrest Brain Injury
Interventions
LUTICIA - Light Utilization COX-Inhibitory Device)
Device
Lead sponsor
Mitovation, Inc
Industry
Eligibility
48 Hours to 1 Year
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Detroit, Michigan
Conditions
Epidermolytic Ichthyosis, Palmoplantar Keratoderma, Pachyonychia Congenita
Interventions
Erlotinib
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2031
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Parkinson Disease
Interventions
Levodopa, Clinical DBS Setting, Sham DBS, DBS Setting Maximizing Prefrontal Activation, DBS Setting Minimizing Prefrontal Activation
Drug · Device
Lead sponsor
Emory University
Other
Eligibility
45 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
2
States / cities
Atlanta, Georgia
Conditions
Metastatic Clear Cell Renal Cell Carcinoma
Interventions
Hydroxychloroquine, RAD001
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
3
States / cities
New Brunswick, New Jersey • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania
Conditions
Healthy Participants
Interventions
Vimseltinib, Metformin
Drug
Lead sponsor
Deciphera Pharmaceuticals, LLC
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Overland Park, Kansas
Conditions
Liver Metastases, Non-small Cell Lung Cancer
Interventions
Liver SBRT, Pembrolizumab
Radiation · Drug
Lead sponsor
VA Ann Arbor Healthcare System
Federal
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Cancer, Hematological Malignancy
Interventions
Pembrolizumab, Ruxolitinib
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
New York, New York
Completed No phase listed Observational Accepts healthy volunteers

EEG and EMG Studies of Hand Dystonia

NCT00025701
Conditions
Focal Dystonia
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 80 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Multiple Myeloma
Interventions
Motixafortide, G-CSF
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 78 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Melanoma
Interventions
Ceralasertib, Durvalumab
Drug · Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
6
States / cities
Los Angeles, California • Sacramento, California • San Francisco, California + 3 more
Conditions
Colorectal Cancer, Colorectal Carcinoma, Colorectal Adenocarcinoma, Refractory Cancer, Colorectal Neoplasms
Interventions
Durvalumab, Tremelimumab, Pexa-Vec
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Metastatic Solid Tumor, SF3B1 Gene Mutation, Spliceosome Mutation, U2AF1 Gene Mutation, SRSF2 Gene Mutation
Interventions
Recommendation for treatment with immunotherapy
Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland